Biohacking Your Sleep: What the Evidence Actually Supports

Sleep is the most heavily optimised subject in biohacking, and the reason is obvious enough. It takes up a third of your life, it affects almost every marker people track, and it is one of the few variables you can change without a prescription. What follows is usually a shopping list: a tracker, blue-light glasses, a cooling mattress topper, magnesium, a dawn simulator, maybe a red light panel.

The difficulty is that the enthusiasm and the evidence are arranged in almost exactly the wrong order. The interventions with the strongest trial support are behavioural, unglamorous and free. The interventions with the weakest support are the ones you can buy. A reasonable way to approach this is to work down the evidence in order of strength rather than in order of how interesting the product is, and to be honest about which tier each thing sits in.

This article does that. It is about sleep in generally healthy adults who want to sleep better, and about chronic insomnia where the evidence base is deepest. It is general information rather than medical advice, and there is a section at the end on the specific symptoms that should send you to a GP instead of to a checkout page.

Cognitive behavioural therapy for insomnia, usually shortened to CBT-I, is the recommended first-line treatment for chronic insomnia, and the evidence behind it is unusually deep. In 2024 a team publishing in JAMA Psychiatry carried out a component network meta-analysis, a design that pulls apart a multi-part treatment to estimate what each individual piece contributes. They pooled 241 randomised trials covering 31,452 adults, with a mean age of 45.4 years, of whom around two thirds were women.

The headline number is worth sitting with. The most efficacious combination the analysis identified, compared against in-person psychoeducation, increased the remission rate by a risk difference of 0.33, with a 95 percent confidence interval of 0.23 to 0.43, giving a number needed to treat of 3.0. In plain terms, on this evidence roughly one in three people treated with a well-constructed CBT-I package reaches remission who would not have done otherwise. Very few things in medicine have a number needed to treat of three, and almost nothing sold as a sleep gadget comes close.

The HSE lists CBT-I among the treatments for insomnia and notes that most people who try it sleep better, with guided self-help, one-to-one and group formats all in use. The JAMA Psychiatry analysis found in-person therapist-led delivery was associated with the largest benefit, with an incremental odds ratio of 1.83 and a confidence interval of 1.19 to 2.81, though digital and self-help formats still had value and are far easier to access. If you are going to spend money on your sleep, this is where the evidence says to spend it first.

The reason the component analysis matters so much for anyone interested in biohacking is that it tested the individual ingredients, and the results are genuinely awkward for most sleep advice in circulation.

The components that carried the benefit were cognitive restructuring, with an incremental odds ratio for remission of 1.68 and a confidence interval of 1.28 to 2.20, third-wave components such as acceptance and mindfulness-based elements at 1.49, sleep restriction at 1.49, and stimulus control at 1.43. Those four, delivered in person, formed the strongest package the analysis could construct.

Sleep hygiene education was not essential. Its incremental odds ratio was 1.01, with a confidence interval of 0.77 to 1.32, which is as close to no independent contribution as a result can get. That is the tier containing almost all popular sleep advice: keep the room dark and cool, no caffeine late, no screens in bed, consistent bedtime. This does not mean those habits are worthless, and the HSE still reasonably recommends them as a starting point, since they are free and harmless. It means that on this evidence, sleep hygiene advice on its own is not what fixes chronic insomnia, and a protocol built entirely from it is unlikely to be enough.

The more surprising finding was that relaxation procedures were potentially counterproductive, with an incremental odds ratio of 0.81 and a confidence interval of 0.64 to 1.02. The authors were careful about this, and the interval crosses 1, so it is a signal rather than a settled conclusion. One plausible reading is that effortful relaxation turns sleep into a performance to be achieved, which is the opposite of what helps. It is worth knowing if you have been diligently doing breathing exercises in bed and getting nowhere.

The two behavioural components that did carry weight are also the two that sound least appealing, which may be why they rarely feature in consumer sleep content.

Stimulus control is about rebuilding the association between your bed and sleeping. If you have had insomnia for a while, your bed has quietly become the place where you lie awake worrying about not sleeping, and your nervous system has learned that. The protocol is to use the bed only for sleep and sex, to get up and leave the room if you are awake and frustrated, and to return only when sleepy. In the component analysis, stimulus control was associated with improved subjective sleep quality, sleep efficiency and sleep latency.

Sleep restriction is more demanding and is the one people abandon. It deliberately shortens the time you spend in bed to match the time you actually spend asleep, then extends it gradually as sleep efficiency improves. It usually makes you feel worse for the first week or two before it works, which is why doing it with a therapist or a structured programme matters. It was associated with improvements in subjective sleep quality, sleep efficiency and wake after sleep onset.

Both carry real caveats. Sleep restriction in particular is not appropriate for everyone, and it should be approached with clinical guidance if you have bipolar disorder, a seizure disorder, untreated obstructive sleep apnoea, or a job where daytime sleepiness is dangerous, such as driving or operating machinery. This is a case where the intervention with the best evidence is also the one that most needs supervision.

Trackers are the entry point to sleep biohacking for most people, and they are genuinely useful for some things and misleading for others. A 2024 systematic review in JMIR mHealth and uHealth screened 504 candidate articles and included eight that validated recent-generation wrist-worn devices against polysomnography, the laboratory reference standard for measuring sleep.

For total sleep time the results were reasonable. WHOOP showed the least disagreement with the reference measurement at 1.4 minutes, with light sleep out by 9.6 minutes and deep sleep by 9.3 minutes. Fitbit Charge 4 and Garmin Vivosmart 4 both showed moderate accuracy for sleep stages and total sleep time. Where the devices struggled was the sleep staging that their apps present most confidently. WHOOP, the most accurate device for total sleep time in the review, was out by 21 minutes on REM sleep. Fitbit Charge 4 did best on REM at 4 minutes of disagreement, with sensitivity of 75 percent for deep sleep and 86.5 percent for REM.

The practical conclusion is to trust the coarse numbers and treat the pretty hypnogram as an estimate. Bedtime, wake time, rough total sleep duration and week-to-week trends are useful. A specific claim that you got forty-one minutes of deep sleep last night is not a measurement you should make decisions on, and the review's own authors noted that all the devices tested would benefit from further improvement on specific sleep stages.

There is also a documented failure mode worth naming. Clinicians use the informal term orthosomnia for anxiety driven by a pursuit of perfect tracker scores, where the tracking itself starts degrading the sleep it is measuring. If checking your score in the morning reliably sets the tone for your day, or you find yourself going to bed earlier to protect a metric rather than because you are tired, the tracker has stopped being a tool. Taking a week off it is a reasonable experiment.

Blue-light filtering glasses are close to a default purchase in sleep biohacking, and the reasoning behind them is sound as far as it goes. Short-wavelength light suppresses melatonin and shifts circadian timing, so filtering it in the evening ought to help. The question is whether the trials show that it does.

A 2023 Cochrane review examined this directly, including 17 randomised controlled trials comparing blue-light filtering spectacle lenses with non-filtering lenses in adults. The trials were small, ranging from five to 156 participants, with follow-up from less than one day to five weeks, and none was judged at low risk of bias across all seven domains assessed.

On sleep quality specifically, the reviewers concluded they do not know whether blue-light filtering lenses are equivalent or superior to ordinary lenses, rating the evidence very low certainty. Six trials with 148 participants between them produced split results: three reported a significant improvement in sleep scores and three found no significant difference. The review also found these lenses may not reduce eye strain from computer use over short follow-up, and probably have little or no effect on visual acuity. Reported adverse effects were infrequent but included headache, discomfort and, in some participants, lower mood.

That is not a finding that the glasses do nothing. It is a finding that the trials so far are too small, too short and too inconsistent to tell, which is a different and more honest statement. If you already own a pair and like them, there is no reason from this evidence to stop. If you are deciding where to put money or effort, this belongs well below CBT-I and below simply reducing evening light levels in the room, which costs nothing.

Light is the main signal your circadian system uses to set its timing, and this is one area where a biohacking-style intervention has direct trial evidence rather than mechanism alone, though the effect is narrower than usually claimed.

A 2023 systematic review and meta-analysis in the Journal of Sleep Research examined light therapy in insomnia disorder, including 22 studies with 685 participants in total and pooling 13 of them. Light therapy significantly improved wake after sleep onset, the time spent awake during the night after first falling asleep, with a standardised mean difference of -0.61 on actigraphy corresponding to a weighted difference of about 11.2 minutes, and a larger effect on sleep diary measures. It did not significantly improve sleep latency, total sleep time or sleep efficiency. The authors noted that heterogeneity between studies and publication bias limit how far the dose-response question can be interpreted.

Direction mattered in a consistent way: morning light exposure advanced the sleep-wake rhythm, meaning earlier sleep and earlier waking, while evening exposure delayed it. That is the practical takeaway, and it is free to act on. If you struggle to fall asleep at a sensible hour, getting outdoor light shortly after waking is the lever with the most support behind it, and Irish daylight, even under heavy cloud, is far brighter than typical indoor lighting. In the darker months a dawn simulator or a light box is a reasonable substitute, and is the one piece of sleep hardware with meaningful trial evidence attached.

Room temperature and a consistent wake time are worth including here too. Both are standard sleep hygiene advice, which the component analysis showed is not sufficient on its own, but both are free, low risk and sensible as a foundation rather than as a treatment.

This is where Irish readers need different information from most sleep content online, because the overwhelming majority of it is written for the United States, where melatonin is sold as a dietary supplement in shops and online.

In Ireland melatonin is a medicine rather than a supplement. The prolonged-release melatonin product authorised here is a prescription-only medicine, and its authorised indication is primary insomnia in adults aged 55 and over. You can check its status on the HPRA register of authorised medicines. That has two consequences. The first is that obtaining melatonin means a conversation with your GP rather than a purchase, and that conversation is the right one to have, because insomnia that has lasted long enough for you to consider medication is insomnia that warrants assessment. The second is that melatonin ordered from overseas websites sits outside that framework, and you have no assurance about what is in it or how much.

Other supplements marketed for sleep, magnesium and various herbal preparations among them, are regulated as food in Ireland rather than as medicines. That means they are not assessed for efficacy the way a licensed medicine is, and a product can be entirely legal to sell while the evidence for the sleep claim attached to it remains thin. Some may help some people. The point is that legal availability is not evidence of effect, and the difference is easy to miss on a shelf.

The HSE also notes that over-the-counter sleep aids may help for one to two weeks but cannot resolve insomnia, and should not be used for longer than that. They can cause next-day drowsiness that affects driving, which is worth factoring in before starting anything.

Self-directed optimisation has a boundary, and knowing where it sits is the most useful thing in this article. The HSE advises seeing a GP if sleep problems have persisted for around a month despite changing your sleep routine, if they are significantly affecting your daily functioning, or if they are making it hard to cope.

There are also specific patterns that no amount of tracking or light timing will address, because they are signs of a condition that needs diagnosis. Loud snoring with pauses in breathing, gasping or choking in the night, and heavy daytime sleepiness despite apparently adequate time in bed can indicate obstructive sleep apnoea, which is common, treatable, and carries cardiovascular consequences if left alone. Persistent early morning waking alongside low mood, loss of interest or hopelessness can be a feature of depression rather than a sleep problem in isolation. An irresistible urge to move your legs in the evening that eases with movement points towards restless legs syndrome. Falling asleep involuntarily during the day warrants prompt assessment.

A tracker can occasionally be genuinely useful here, not because its staging is accurate but because a consistent pattern of low oxygen saturation readings or heavy night-time movement gives you something concrete to bring to an appointment. Use it as a prompt to seek assessment rather than as a substitute for one.

The overall picture is less exciting than a protocol but more useful. Get morning daylight, keep a consistent wake time, keep the room dark and cool as a foundation, and treat your tracker as a rough trend line rather than a laboratory. If sleep is genuinely a problem rather than something you want to optimise at the margins, ask your GP about CBT-I, because it is the only item on this list with a number needed to treat of three behind it.